The OrthoGlide(TM) Medial Knee Implant Continues to be Accepted as an Alternative to Total Knee R... ( Over 300 implants reported in the int...)

The OrthoGlide(TM) Medial Knee Implant Continues to be Accepted as an Alternative to Total Knee Replacement

Date:11/6/2007

Over 300 implants reported in the intended patient population for company's

minimally invasive knee implant.

MINNEAPOLIS, Nov. 6 /PRNewswire/-- Advanced Bio-Surfaces, Inc., (ABS) an orthopedic implant developer and manufacturer, announced today the OrthoGlide Medial Knee Implant has been implanted in more than 300 patients in the USA. The OrthoGlide implant is a minimally invasive device intended to relieve pain caused by moderate osteoarthritis of the knee.

"The interest from surgeons and patients for a minimally invasive alternative to the current knee replacement options on the market continues to expand," said Dr. Jeff Felt, Chairman of Advanced Bio-Surfaces. "We have increased the number of training sites in the United States in an effort to accommodate the number of interested surgeons. As the surgeon community learns more about the product and its minimal surgical approach, they understand the need for the OrthoGlide implant as a viable option for some patients. The growth is inspired by surgeons who want to be trained on a procedure that can be positioned as an alternative to total knee replacement."

In addition to training and supporting the orthopedic surgeon community interested in the OrthoGlide implant, ABS is also involved in a clinical study. This week, during the American College of Rheumatology's annual meeting in Boston, MA, William Arnold, M.D. will present data from the study that supports the OrthoGlide's clinical effectiveness. The presentation will be held in Room 153 of the Boston Convention and Exhibit Center at 5:30 p.m. on Saturday, November 10th.

About Advanced Bio-Surfaces, Inc.

ABS is a privately held company dedicated to the development of innovative joint restoration products. The company's first product, the OrthoGlide Medial Knee Implant, is intended for the treatment of patients with moderate osteoarthritis of the medial compartment. The company received 510(k) clearance to
'/>"/>

2

GOOD

Page: 1 2
Related medicine technology :

1. Preimplantation Genetic Diagnosis International Society Refutes American Society of Reproductive Medicine Opinion - States Preimplantation Genetic Screening is Beneficial When Performed in Experienced Centers
2. Adult Smoking Rate Continues Downward Trend
3. Gilbert Hospital Continues Cutting Edge Treatments
4. ORENCIA(R) (abatacept) Supplemental Biologics License Application for Juvenile Idiopathic Arthritis Accepted by FDA for Filing and Review
5. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
6. Iomai Announces Data from Phase 2 Field Study of Travelers Diarrhea Vaccine Accepted for Presentation at ICAAC
7. Four Analyses of Three-Year Clinical Data Suggest CYPHER(R) Sirolimus-Eluting Coronary Stent May Provide Alternative to Surgery for Patients with Multivessel Disease
8. Spine Institute of Louisiana Offers Cervical Spine Motion Preservation as an Alternative to Fusion Surgery
9. Anesiva Initiates Phase 2 Trial with Adlea(TM) for Pain Relief Following Total Hip Replacement Surgery
10. Anesiva Initiates New Phase 2 Trial of Adlea(TM) for Pain Relief Following Knee Replacement Surgery
11. Facet Solutions Enjoys Continued Clinical Success With the Anatomic Facet Replacement System (AFRS(TM))

Post Your Comments:

The OrthoGlide(TM) Medial Knee Implant Continues to be Accepted as an Alternative to Total Knee R...( Over 300 implants reported in the int...),Health